European Commission President Ursula von der Leyen said it all depended on the results of the European Medicines Agency’s assessment of the two anti-COVID sera. In the second half of December, the EU could give the green light to these vaccines, reporters show Digi 24.

The head of the European Commission reminds that the Union has beaten 5 producers of COVID vaccines. The advantage is that the sera use 4 different technologies that could be effective for various segments of the population.

“The European Medicines Agency (EMA) is in daily contact with the FDA (similar body in the United States) to synchronize vaccine evaluation and if all goes well, the EMA says the marketing authorization for Biontech and Moderna vaccines could be released in the second half of December 2020, ”said Von der Leyen.

“We have adopted 5 contracts with BionTech, CureVac, Astra / Zeneca, Johnson & Johnson and Sanofi. We are continuing negotiations with Moderna and are in talks with Novavax. It was gratifying to see that all Member States have agreed to buy these vaccines and stay in our portfolio. This portfolio of 5 vaccines, hopefully 6 soon, is important because it covers four different production technologies. Maybe some vaccines work better in some parts of the population than others, “she added.

Read also:

EU Summit. What is Poland relying on in the EU blackmail operation

BioNTech: The application for authorization of the anti-COVID vaccine will be submitted tomorrow. It is possible to launch it in December